Victory Capital Management
MLYS icon

Victory Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

Victory Capital Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$898K Buy
33,141
+260
+0.8% +$7.63K ﹤0.01% 1883
2025
Q4 		$1.19M Buy
32,881
+27,174
+476% +$1.09M ﹤0.01% 1745
2025
Q3 		$216K Buy
+5,707
New +$123K ﹤0.01% 2210

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Victory Capital Management's MLYS Position: Q1 2026 in Review

Victory Capital Management increased its Mineralys Therapeutics (MLYS) stake by 0.79% in Q1 2026, buying an estimated $7.63K and bringing the position to 33,141 shares worth $898K. The position accounts for ﹤0.01% of the portfolio, ranked #1883.

Victory Capital Management first reported a position in MLYS in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.19M in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Victory Capital Management held 33,141 shares of Mineralys Therapeutics worth $898K as of Q1 2026.
  • Victory Capital Management bought 260 Mineralys Therapeutics shares in Q1 2026, an estimated $7.63K.
  • Mineralys Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #1883 holding.
  • Victory Capital Management first reported a position in Mineralys Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Victory Capital Management's Mineralys Therapeutics position peaked at $1.19M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.